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2008 to 2010. Of the 34 patients treated with Talent grafts, two
patients were complicated with a device-related retrograde dissec-
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Dr Ben Starnes (Seattle, Wash). I have the following ques-
tions for the authors:
The goal of this therapy is to prevent death due to aneurysm
rupture and NOT to treat the underlying dissection. Did any
patient in this series continue to expand over the follow-up period,
and more importantly, did any patient go on to rupture and die?
Dr Iden David Andacheh. Given the fact that our study
population was part of an FDA-approved investigational device
exemption (IDE), patient mortality has been closely followed. As
previously mentioned, there were two cases of rupture within the
30-day postoperative period. Since the publication of these data,
we have had two patients who required debranching procedures as
a result infrarenal aortic expansion during long-term follow-up.
No patient has died due to rupture during long-term follow-up.
Dr Starnes. Described in this series are four cases of retro-
grade aortic dissection leading to death. The Medtronic Talent
device has an uncovered proximal stent to aid in fixation and
the company recently added a tip-capture mechanism (Valiant-
Captivia) to avoid a commonly observed deployment deficiency
described as “retroflexion” of this uncovered stent. Do the authors
believe that this device, with its uncovered proximal stent, is the
best device for managing dissections, and furthermore, have any
lethal retrograde dissections been observed since using the new
graft?
Dr Andacheh. Our institution used the Medtronic Talent
device from 2002 to 2007 and the Valiant-Captivia device fromion. By comparison, one out of the 39 patients treated with
aliant-Captivia grafts had a device-related retrograde dissection.
his may suggest a benefit to using the Valiant-Captivia device, but
learly, further analysis is needed.
Dr Starnes. As we all know, most type B dissections begin at
he left subclavian artery and thus an adequate proximal seal may
equire a debranching procedure such as a carotid-subclavian
ypass to achieve success. How often was a debranching procedure
one in this series? Along those lines, what was the rate of type I
ndoleak?
Dr Andacheh. A debranching procedure was required in four
ut of the 72 treated patients. Of the seven patients treated for
ndoleak, four were for a type I endoleak.
Dr Starnes. What was the role of neural protection in your
eries to prevent the dreaded complication of paraplegia? Was
pinal drainage used, and if so, what were the indications to do so?
Dr Andacheh. Spinal drain was not routinely used. Intraop-
rative maintenance of MAP pressures was used to reduce the risk
f paraplegia. Placement of a spinal drain was considered when
ubclavian artery coverage was required.
Dr Starnes. Finally, can the authors please expand on any
echniques or strategies for obliterating false lumen flow with coils
r glue or some sort of obliterative therapy to increase rates of
avorable aortic remodeling?
Dr Andacheh.We have not used coils, glue, or other obliter-
tive therapies. We rely on adequate proximal exclusion and re-
odeling of the aorta. We have only intervened by adding addi-
ional devices when the source of aortic expansion was identified.
